Wakamoto PharmaceuticalWAKAMOTO PHARMACEUTICAL CO.,LTD.4512東証スタンダード医薬品FY ending Mar 2026, non-consolidated, J-GAAP
Out of every ¥100 of sales, about ¥3 is left as operating profit. Revenue changed +27.2% from the prior year, and it swung back to an operating profit.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 2.8% | 0.56× | 1.6% | 1.41× | 2.2% |
| 2023 | 1.6% | 0.56× | 0.9% | 1.44× | 1.3% |
| 2024 | 1.4% | 0.50× | 0.7% | 1.45× | 1.0% |
| 2025 | 0.8% | 0.51× | 0.4% | 1.42× | 0.6% |
| 2026 | 2.3% | 0.63× | 1.4% | 1.46× | 2.1% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 8,383 | 8,660 | 7,738 | 7,789 | 9,907 |
| Cost of revenue | 4,027 | 4,552 | 4,139 | 4,167 | 5,176 |
| Gross profit | 4,356 | 4,108 | 3,600 | 3,622 | 4,730 |
| SG&A | 4,369 | 3,967 | 3,795 | 4,080 | 4,475 |
| Operating income | -13 | 141 | -196 | -458 | 256 |
| Pretax income | 285 | 212 | 159 | 7 | 256 |
| Income tax | 46 | 73 | 50 | -57 | 29 |
| Net income attributable to owners | 239 | 138 | 109 | 64 | 227 |
| Operating margin | -0.2% | 1.6% | -2.5% | -5.9% | 2.6% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.23B | ¥3.88B | ¥3.66B | ¥2.95B | ¥2.01B |
| Total assets | ¥15B | ¥15.7B | ¥15.4B | ¥15B | ¥16.5B |
| Net assets | ¥11.5B | ¥11.9B | ¥12B | ¥11.6B | ¥12B |
| Share capital | ¥3.4B | ¥3.4B | ¥3.4B | ¥3.4B | ¥3.4B |
| Property, plant and equipment | ¥3.3B | ¥3.03B | ¥3.03B | ¥3.31B | ¥3.66B |
| Intangible assets excluding goodwill | ¥196.1M | ¥202.1M | ¥357M | ¥277.7M | ¥241.5M |
| Investment securities | ¥2.07B | ¥2.48B | ¥2.44B | ¥1.85B | ¥2.25B |
| Current assets | ¥8.61B | ¥9.35B | ¥8.97B | ¥8.91B | ¥9.67B |
| Current liabilities | ¥2.01B | ¥2.24B | ¥1.81B | ¥2.03B | ¥2.78B |
| Short-term borrowings | ¥100M | ¥100M | ¥100M | ¥100M | ¥100M |
| Long-term borrowings | — | — | — | — | ¥261.5M |
| Total liabilities | ¥3.47B | ¥3.8B | ¥3.39B | ¥3.39B | ¥4.49B |
| Equity attributable to owners of parent | ¥10.6B | ¥10.7B | ¥10.7B | ¥10.7B | ¥10.8B |
| Retained earnings | ¥4.57B | ¥4.71B | ¥4.71B | ¥4.67B | ¥4.79B |
| Treasury stock | -¥36.3M | -¥36.4M | -¥36.4M | -¥36.5M | -¥36.6M |
EDINET (FSA Japan)
有価証券報告書－第131期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第130期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第129期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第128期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第127期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第126期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 47 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.